Drug Trial Radar · NCT01887600
Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis
Last checked: Nov 19, 2026Latest source record: Nov 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
594
Actual
Start
Sep 3, 2013
Primary completion
Nov 1, 2017
Study completion Nov 1, 2017
Sponsor
- Lead sponsor
- Astellas Pharma Europe B.V.Astellas (ALPMY)
- Sponsor type
- Industry
- Collaborators
- Kyntra Bio
- First posted
- Jun 27, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was conducted to treat anemia in patients with chronic kidney disease. Anemia is a reduced number of red blood cells or hemoglobin. Hemoglobin is important for the transport of oxygen in your blood. The purpose of the study was to see if Roxadustat is both effective and safe as a treatment for anemia in patients with chronic kidney disease.
Conditions
- Anemia in Chronic Kidney Disease in Non-dialysis Patients
Interventions
RoxadustatDrug
Roxadustat was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
PlaceboDrug
Placebo was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Hemoglobin (Hb) Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy Prior to Hb ResponseTime frame: Baseline to week 24
- Hb Change From Baseline (BL) to the Average Hb in Weeks 28-52 Regardless of Rescue TherapyTime frame: Baseline and weeks 28 to 52
Locations
138 sites in 22 countries. Site status is shown where the registry gives one.
Site BY37503
Brest, Belarus
Site BY37501
Grodno, Belarus
Site BY37504
Homyel, Belarus
Site BY37506
Minsk, Belarus
Site BY37507
Minsk, Belarus
Site BY37505
Minsk, Belarus
Site BY37502
Vitebsk, Belarus
Site BE32002
Antwerp, Belgium
Site BE32012
Baudour, Belgium
Site BE32017
Bonheiden, Belgium
Site BE32014
Ieper, Belgium
Site BE32013
Liège, Belgium
Site BE32004
Brussels, Flemish Brabant, Belgium
Site BG35923
Pazardzhik, Bulgaria
Site BG35906
Sofia, Bulgaria
Site BG35908
Sofia, Bulgaria
Site BG35910
Sofia, Bulgaria
Site BG35907
Stara Zagora, Bulgaria
Site BG35916
Varna, Bulgaria
Site BG35903
Veliko Tarnovo, Bulgaria
Site CO57007
Barranquilla, Colombia
Site CO57008
Barranquilla, Colombia
Site CO57002
Pereira, Colombia
Site DO17101
La Fe Santo Domingo, Dominican Republic
Site DO17102
Santiago de los Caballeros, Dominican Republic
Site DO17104
Santo Domingo, Dominican Republic
Site DO17103
Santo Domingo, Dominican Republic
Site EE37201
Tallinn, Estonia
Site GE99503
Tbilisi, Georgia
Site GE99504
Tbilisi, Georgia
Site GE99502
Tbilisi, Georgia
Site GR30003
Heraklion, Greece
Site GR30002
Pátrai, Greece
Site GR30001
Thessaloniki, Greece
Site GT50209
Chiquimula, Guatemala
Site GT50205
Guatemala City, Guatemala
Site GT50206
Guatemala City, Guatemala
Site GT50203
Guatemala City, Guatemala
Site GT50202
Guatemala City, Guatemala
Site GT50208
Guatemala City, Guatemala
Showing 40 of 138 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.